![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Cullinan Therapeutics, Inc., formerly Cullinan Oncology, Inc., is a biopharmaceutical company focused on developing modality-agnostic targeted therapies. It has a portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both o... Cullinan Therapeutics, Inc., formerly Cullinan Oncology, Inc., is a biopharmaceutical company focused on developing modality-agnostic targeted therapies. It has a portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its pipeline includes CLN-619, CLN-978, Zipalertinib (CLN-081/TAS6417), CLN-049, CLN-418, and CLN-617. Its lead unpartnered program, CLN-619, is a humanized lgG1 monoclonal antibody (mAb) that binds to the stress induced ligands MICA and MICB (MICA/B), which are expressed on a variety of solid tumors and hematologic malignancies. CLN-978 is a novel, highly potent, half-life extended CD19xCD3 bispecific T cell engager construct. CLN-081/TAS6417 is a novel, orally available, covalent inhibitor of mutant epidermal growth factor receptor (EGFR). CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-418 is a B7H4 x 4-1BB bispecific immune activator. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.71 | -7.1 | 10 | 10.27 | 9.22 | 291598 | 9.70700419 | CS |
4 | -1.08 | -10.4146576663 | 10.37 | 11.92 | 9.22 | 431782 | 10.38293801 | CS |
12 | -3.2 | -25.6204963971 | 12.49 | 13.78 | 9.22 | 518574 | 11.448074 | CS |
26 | -7.37 | -44.237695078 | 16.66 | 19.89 | 9.22 | 524436 | 14.44307114 | CS |
52 | -8.83 | -48.7306843267 | 18.12 | 30.1886 | 9.22 | 651430 | 17.82537122 | CS |
156 | -5.06 | -35.2613240418 | 14.35 | 30.1886 | 7.3 | 392663 | 14.97242067 | CS |
260 | -32.71 | -77.880952381 | 42 | 59.85 | 7.3 | 356595 | 17.59143763 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions